Nintedanib
| Evidence Level: L5 | Predicted Indications: 55 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Nintedanib |
| DrugBank ID | DB09079 |
| Brand Names (EU) | Nintedanib Accord, Ofev, Vargatef |
| Evidence Level | L5 |
| Predicted Indications | 55 |
| Top Prediction Score | 99.15% |
Approved Indication (EMA)
Vargatef is indicated in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first line chemotherapy.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | dermatofibrosarcoma protuberans | 99.15% | DL |
| 2 | liposarcoma | 99.13% | DL |
| 3 | ovarian myxoid liposarcoma | 99.12% | DL |
| 4 | heart fibrosarcoma | 98.88% | DL |
| 5 | axial spondylometaphyseal dysplasia | 98.87% | DL |
| 6 | amyotrohpic lateral sclerosis type 22 | 98.86% | DL |
| 7 | fibroblastic neoplasm | 98.84% | DL |
| 8 | kidney fibrosarcoma | 98.83% | DL |
| 9 | conventional fibrosarcoma | 98.81% | DL |
| 10 | amyotrophic lateral sclerosis, susceptibility to | 98.80% | DL |
| 11 | amyotrophic lateral sclerosis | 98.78% | DL |
| 12 | bilateral parasagittal parieto-occipital polymicrogyria | 98.75% | DL |
| 13 | low grade fibromyxoid sarcoma | 98.74% | DL |
| 14 | trichomegaly-retina pigmentary degeneration-dwarfism syndrome | 98.66% | DL |
| 15 | Mills syndrome | 98.63% | DL |
| 16 | familial rhabdoid tumor | 98.51% | DL |
| 17 | lower motor neuron syndrome with late-adult onset | 98.47% | DL |
| 18 | extracutaneous mastocytoma | 98.46% | DL |
| 19 | monomelic amyotrophy | 98.31% | DL |
| 20 | autosomal dominant mitochondrial myopathy with exercise intolerance | 98.25% | DL |
Showing top 20 of 55 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.